Study of Simultaneous Modulated Accelerated Radiation Therapy Concurrent With Chemotherapy to Treat Esophageal Cancer

• Status: Completed
• Trial end date: 2015-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the acute and 2-year late toxicities, the 2-year local control and overall survival rates in patients with esophageal squamous cell carcinoma receiving simultaneous modulated accelerated radiation therapy concurrent with chemotherapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chuangzhen Chen
• Treatments: Cisplatin; Fluorouracil

Criteria

Inclusion Criteria:

• pathological proven diagnosis of primary squamous cell carcinoma of the esophagus

• the primary disease located in cervical, upper or middle thoracic esophagus

• no distant metastases

• zubrod performance status: 0~2

• life expectancy > 6 months; -absence of another malignancy

• adequate liver, renal and bone marrow function

• women of childbearing potential and male participants must practice adequate contraception

• patient must provide study-specific informed consent prior to study entry

Exclusion Criteria:

• evidence of tracheoesophageal or Mediastinal-esophageal fistula

• prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 2 years

• prior radiation therapy that would result in overlap of planned radiation therapy fields; - Severe, active comorbidity

• pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception

• women who are nursing